Pyruvate kinase drugs for Transfusion-Dependent Beta Thalassemia
2 tracked Pyruvate kinase drugs in the Transfusion-Dependent Beta Thalassemia race. The class explanation lives on the Pyruvate kinase page; the full indication pipeline across every mechanism is on the Transfusion-Dependent Beta Thalassemia page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Mitapivat vs Mitapivat (Aqvesme)